E Fund Management Co. Ltd. Has $532,000 Stock Position in Insmed Incorporated (NASDAQ:INSM)

E Fund Management Co. Ltd. boosted its position in shares of Insmed Incorporated (NASDAQ:INSM) by 22.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,178 shares of the biopharmaceutical company’s stock after acquiring an additional 3,130 shares during the period. E Fund Management Co. Ltd.’s holdings in Insmed were worth $532,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. International Assets Investment Management LLC acquired a new position in shares of Insmed during the 4th quarter worth about $25,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Insmed by 106.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,698 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 1,910 shares during the last quarter. Assetmark Inc. boosted its position in shares of Insmed by 10.7% in the third quarter. Assetmark Inc. now owns 4,799 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 463 shares during the period. Mackenzie Financial Corp acquired a new stake in shares of Insmed in the third quarter worth $208,000. Finally, Xponance Inc. bought a new position in Insmed during the fourth quarter worth $259,000.

Insmed Stock Performance

Insmed stock traded down $0.08 on Wednesday, reaching $26.00. The company’s stock had a trading volume of 1,852,514 shares, compared to its average volume of 1,742,237. The business’s fifty day moving average price is $26.61 and its 200 day moving average price is $27.07. The company has a market cap of $3.86 billion, a price-to-earnings ratio of -4.87 and a beta of 0.93. Insmed Incorporated has a twelve month low of $18.08 and a twelve month high of $32.00.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.15). The business had revenue of $83.70 million for the quarter, compared to analysts’ expectations of $82.15 million. During the same quarter in the prior year, the company posted ($1.20) earnings per share. The firm’s revenue was up 41.1% on a year-over-year basis. As a group, equities analysts forecast that Insmed Incorporated will post -4.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

INSM has been the topic of several research analyst reports. Truist Financial initiated coverage on shares of Insmed in a research report on Tuesday, April 23rd. They issued a “buy” rating and a $48.00 price target on the stock. Guggenheim raised their price objective on Insmed from $52.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. UBS Group assumed coverage on Insmed in a research report on Tuesday, February 27th. They set a “buy” rating and a $46.00 price objective on the stock. Wells Fargo & Company reiterated an “overweight” rating and set a $55.00 price target on shares of Insmed in a research note on Monday, April 1st. Finally, Barclays increased their price objective on shares of Insmed from $37.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 11th. One investment analyst has rated the stock with a sell rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and a consensus target price of $44.92.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.